All In Biotech

Drug Trial Radar · NCT05237947

Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial

Single-Dose HPV Vaccination Among Young Adult Women in Costa Rica: the PRISMA-ESCUDDO Trial (PRevencIón Del Cáncer Cervical Con Una Sola Dosis de Vacuna Contra VPH en Mujeres Adultas Jóvenes)

Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 5,000 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

5,000

Planned (sponsor's estimate)

Start

Mar 1, 2022

Primary completion

Jan 15, 2027

Study completion Jan 14, 2028

Sponsor

Sponsor type
NIH
First posted
Feb 14, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 30 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This phase IV trial tests whether a single dose of the human papillomavirus (HPV) vaccine works in preventing cervical cancer in young women in Costa Rica. Human papilloma viruses, called HPV, are a group of viruses that very frequently cause infection in both men and women, mainly in the genital organs. There are many types of HPV, and some can cause cancer. The World Health Organization recommends a two-dose schedule for adolescents 9-14 and three doses for individuals 15 years old or older. This study examines whether a single dose of HPV vaccine can reduce the frequency with which women between ages 18-30 become infected with HPV.

Conditions

  • Human Papillomavirus-Related Cervical Carcinoma

Interventions

  • Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine AdsorbedBiological

    Given IM

  • Questionnaire AdministrationOther

    Ancillary studies

  • Recombinant Human Papillomavirus Bivalent VaccineBiological

    Given IM

  • Recombinant Human Papillomavirus Nonavalent VaccineBiological

    Given IM

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incident persistent human papillomavirus (HPV) 16 or 18 infectionTime frame: 6-month persistence observed during follow-up

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Agencia Costarricense de Investigaciones Biomédicas (ACIB)

    Liberia, Guanacaste Province, Costa Rica

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.